Based on these findings, it is hypothesized that WD-induced obesity may be involved in the development of de novo psoriasis-like skin lesions or the worsening of pre-existing psoriasis in patients undergoing anti-PD-1 therapy, although the exact mechanism remains unknown [88,89]. Here, PDCD1 is linked to Wilson disease.